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Objective To examine the effect of maternal exposure to asthma
medications on the risk of congenital anomalies.
Design Meta-analysis of aggregated data from three cohort
studies.
Setting Linkage between healthcare databases and EUROCAT
congenital anomaly registries.
Population 519 242 pregnancies in Norway (2004–2010), Wales
(2000–2010) and Funen, Denmark (2000–2010).
Methods Exposure defined as having at least one prescription for
asthma medications issued (Wales) or dispensed (Norway,
Denmark) from 91 days before to 91 days after the pregnancy
start date. Odds ratios (ORs) were estimated separately for each
register and combined in meta-analyses.
Main outcome measures ORs for all congenital anomalies and
specific congenital anomalies.
Results Overall exposure prevalence was 3.76%. For exposure to
asthma medication in general, the adjusted OR (adjOR) for a
major congenital anomaly was 1.21 (99% CI 1.09–1.34) after
adjustment for maternal age and socioeconomic position. The OR
of anal atresia was significantly increased in pregnancies exposed
to inhaled corticosteroids (3.40; 99% CI 1.15–10.04). For severe
congenital heart defects, an increased OR (1.97; 1.12–3.49) was
associated with exposure to combination treatment with inhaled
corticosteroids and long-acting beta-2-agonists. Associations with
renal dysplasia were driven by exposure to short-acting beta-2-
agonists (2.37; 1.20–4.67).
Conclusion The increased risk of congenital anomalies for women
taking asthma medication is small with little confounding by
maternal age or socioeconomic status. The study confirmed the
association of inhaled corticosteroids with anal atresia found in
earlier research and found potential new associations with
combination treatment. The potential new associations should be
interpreted with caution due to the large number of comparisons
undertaken.
Keywords Asthma medication, congenital anomalies, first
trimester exposure, inhaled beta-2 agonists, inhaled
corticosteroids.
Tweetable abstract This cohort study found a small increased risk
of congenital anomalies for women taking asthma medication.
Please cite this paper as: Garne E, Vinkel Hansen A, Morris J, Jordan S, Klungsøyr K, Engeland A, Tucker D, Thayer DS, Davies GI, Nybo Andersen A-M,
Dolk H. Risk of congenital anomalies after exposure to asthma medication in the first trimester of pregnancy – a cohort linkage study. BJOG 2016;
DOI: 10.1111/1471-0528.14026.
Introduction
Use of medication in pregnancy may also expose the fetus
to the medication. Exposure during the first trimester of
pregnancy has the potential to increase the risk of
congenital anomalies. Pregnant women with asthma often
have to continue their medication during pregnancy.1
Asthma treatment today is mainly administered by inhala-
tion therapy, which reduces the systemic effects of the
medications. The treatment is based on a stepwise
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approach. Asthma is managed with inhaled short-acting
beta-2-agonists (SABA) for symptom relief, with the
addition of inhaled corticosteroids and other medicines,
preferably as inhalation medicine, when control becomes
reduced.2 Previous studies have shown a slightly increased
risk of congenital anomalies in infants born to women with
asthma 3,4 but it is still unclear whether the aetiology is the
asthma disease (inflammation, hypoxia), the medications
used for treatment or a combination.
A literature review found nine significant associations for
first trimester exposure to beta-2-agonists with the follow-
ing specific congenital anomalies: spina bifida, cleft palate,
cleft lip with or without cleft palate, severe congenital heart
disease (CHD), tetralogy of Fallot, oesophageal atresia, anal
atresia, omphalocele and gastroschisis.5 For exposure to
inhaled corticosteroids, five associations have been pub-
lished: cleft palate, cleft lip with and without cleft palate,
anal atresia, omphalocele and hypospadias. The EUROme-
diCAT case-malformed control study including 13 Euro-
pean congenital anomaly registries with 1301 malformed
registrations exposed to asthma medication, was able to
confirm two of these previous findings: cleft palate and gas-
troschisis, both after exposure to inhaled beta-2-agonists.5
That study could not assess total congenital anomaly risk,
as it did not include non-malformed controls.
Asthma has been reported with increasing prevalence
over the last decades,6 including an Increase in the preva-
lence of asthma in pregnancy.7 Therefore, more fetuses are
now exposed to asthma medications during pregnancy.
The aim of this EUROmediCAT study is to evaluate the
risk of all and specific congenital anomalies in women
reported as exposed to asthma medications in the begin-
ning of pregnancy using data from prescription databases
linked to birth registries and EUROCAT congenital anom-
aly registries in three European regions and countries
where such linkage was possible.
Material and methods
Study design
Odds ratios (ORs) for a major congenital anomaly and a
number of specific congenital anomalies with exposure to
asthma medications in the first trimester of pregnancy were
estimated in each of three population-based cohorts and
the estimates were combined in meta-analyses.
Setting
Three congenital anomaly registers in Norway, Wales and
the Funen region of Denmark, all contributors to the Euro-
pean Network EUROCAT (European Surveillance of
Congenital Anomalies), were linked to their source popula-
tions and healthcare databases. All three congenital anomaly
registers are population-based and collect data on all major
congenital anomaly cases for all pregnancy outcomes [live
births, fetal deaths from 20 weeks of gestation and termina-
tions of pregnancy at any gestational age (GA) for fetal
anomalies] in their respective populations.8 The EUROCAT
registries are based on multiple data sources and detailed
description of the registries and the common methodology
has been published previously.9 Prescription data, also popu-
lation-based, were collected prospectively in all healthcare
databases. The Danish and Norwegian prescription registries
capture information on pharmacy redemption of prescrip-
tions, and capture all dispensed prescriptions from all phar-
macies. Only medicines given to inpatients during a hospital
stay are missed. The Wales database captures prescriptions
issued in primary care.10
For Norway, the Medical Birth Registry of Norway,11
containing all EUROCAT congenital anomaly cases, was
linked to the Norwegian Prescription Database, which
included prescriptions redeemed at a pharmacy since
2004,12 and to the National Education Database, which
provides information on maternal educational level at the
time of linkage. In Wales, existing routinely collected data
from the all-Wales health and social care linked electronic
databank [the Secure Anonymised Information Linkage
(SAIL)] were interrogated.13,14 Data from the Office of
National Statistics birth and deaths registry, the National
Community Child Health Database (NCCHD), the Patient
Episode Database for Wales, and primary care records were
linked to the Congenital Anomaly Register and Information
Service for Wales (CARIS). Primary care prescribing
records were available from 91 days before pregnancy start
date to delivery for 117 717/357 989 (33%) live- and still-
births and for terminations of pregnancy for fetal anoma-
lies. Socioeconomic position was captured as Townsend
scores, ranks and quintiles.15
For Denmark, live- and stillbirths in the county of Funen
recorded in the Danish Medical Birth Registry16 and
TOPFA recorded in the National Patient Register were
linked to the National Prescription Registry17 and to the
Danish EUROCAT registry, covering congenital anomaly
cases in Funen. Maternal education at time of pregnancy
end was used as a measure of socioeconomic status.
Databases were linked using unique personal identifiers
and anonymised. Ethical and data access approvals were
obtained for each database from the relevant governance
infrastructures.
Study population
The study population consisted of all liveborn infants, still-
births/late fetal deaths after 20 completed weeks of gesta-
tion in the three populations and terminations of
pregnancies at any GA due to fetal anomaly (TOPFA)
recorded in the EUROCAT registry, with delivery date or
date of termination between 1 January 2000 and 31
2 ª 2016 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
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December 2010. As the Norwegian Prescription Database
was established in 1 January 2004, Norway was only able to
contribute data for pregnancies where the date of last men-
strual period was 1 April 2004 or later. For Wales, fetal
deaths were only included from 24 completed weeks of
pregnancy.
Pregnancy start date was computed primarily based on
ultrasound estimation of GA using information on date of
last menstrual period where this was missing. If both were
missing (0.34% in Denmark, 2.9% in Wales), Denmark
and Wales used median GA for their registries for live
births, fetal deaths and terminations, respectively, and
Norway discarded the observation (0.56%).
Exposure
Exposure was defined as the mother having redeemed
(Denmark and Norway) or been issued (Wales) at least
one prescription for an asthma medication (ATC code
R03) in the time period from 91 days before to 91 days
after pregnancy start date. Exposure was grouped based on
5-digit ATC codes into six asthma medication classes: all
asthma medications (ATC-code R03), inhaled beta-2-
agonists (R03AC), beta-2-agonists for systemic use (R03CC),
inhaled glucocorticoids (R03BA), combined long-acting
beta-2-agonists and inhaled steroids [R03AK or a prescrip-
tion of both inhaled steroids and a long acting beta-2-
agonists (R03AC12-R03AC13)] and leukotriene receptor
antagonists (R03DC). Inhaled beta-2-agonists were further
divided into two groups: short-acting beta-2-agonists
(SABA) and long-acting beta-2-agonists (LABA) (ATC codes
R03AC02-R03AC04 and R03AC12-R03AC13, respectively).
Exposure to systemic glucocorticoids in combination with an
asthma medication was analysed as a separate outcome, pre-
sumed to be an indicator of high asthma severity.
Infants were excluded if information on maternal pre-
scriptions was missing or incomplete, or if the mother had
a prescription for an antiepileptic or antidiabetic medica-
tions between 91 days before and 91 days after pregnancy
start date. These exclusions were applied to both groups
(exposed and non-exposed to asthma medications).
After review of the results, a sensitivity analysis was per-
formed with a more strict definition of exposure. Here
exposure was defined as a prescription for an asthma medi-
cation (ATC code R03) in the time period from 91 days
before to 91 days after pregnancy start date and at least
two prescriptions for the same medication at two different
time periods from 1 year before pregnancy to the end of
pregnancy.
Outcomes
The outcome was specific major congenital anomalies
recorded in the EUROCAT registry for each region, classi-
fied according to EUROCAT standard subgroups.9 Infants
and fetuses with diagnosed chromosomal, genetic or terato-
genic anomalies or with skeletal dysplasias were excluded
(known aetiology).
Statistical analyses
As none of the registries was able to send data on individu-
als out of the country, analyses were done on aggregated
data. Odds ratios for each registry were computed and
combined using Mantel–Haenszel methods with variable
continuity corrections for empty cells proportional to size
of case group relative to control group and summing to
1.18 Confidence intervals for combined estimates were cal-
culated using Cornfield approximation. The I2-statistic,
describing the percentage of variation explained by hetero-
geneity, was computed for the meta-analyses.
For outcomes and exposures with at least 15 exposed
cases, logistic regression was used to adjust for maternal
age and socioeconomic position, again running analyses in
each registry separately and combining estimates in a meta-
analysis using a random effects model.
Odds ratio (OR) of exposure to asthma medications in
general, or to each of seven asthma medication classes, was
calculated for each of 62 EUROCAT congenital anomaly
subgroups. Only associations with at least three exposed
cases are reported. Due to the large number of tests, 99%
confidence intervals are shown. As the outcomes are rare,
ORs are close approximations to relative risks.
The software used for combining estimates was
STATA13. Plots were created in R and modified in
Inkscape.
Results
Of the 519 242 infants and fetuses included in the study,
19 513 mothers had a prescription for asthma medication
within the defined exposure period from 91 days before to
91 days after the pregnancy start date, giving an overall
exposure prevalence at 3.76%. Exposure prevalence by
region was 3.66% in Denmark, 2.85% in Norway and
6.51% in Wales (Table 1). Inhaled beta-2-agonists were the
most frequently prescribed asthma medications (2.93%
exposed), 1.16% were exposed to inhaled steroids and
1.19% to combination treatments (inhaled steroids and
LABA). Socio-demographic data by region are presented in
Table S1.
Among the exposed pregnancies, 650 fetuses and infants
were registered with a major congenital anomaly. Exposure
to any asthma medication (ATC code R03) compared with
no exposure was associated with an increased risk of any
congenital anomaly: adjusted OR (adjOR) = 1.21 (99% CI
1.09–1.34). Table 2 presents ORs and adjORs for a major
congenital anomaly as one group after exposure to different
types of asthma medications.
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Figure 1 shows meta-analysis ORs and 99% confidence
intervals for each of the medication groups and each of
the anomaly subgroups. Table 3 shows combined OR
estimates and the I2-statistic (the percentage of the varia-
tion explained by heterogeneity) for all statistically signif-
icant associations. For the associations with high
heterogeneity, the explanation is partly sparse data and
partly actual heterogeneity; all associations with I2 > 50
had very high OR in Denmark based on very few cases.
Among these, the significant associations with limb
reduction were not present in Norway (apart from for
exposure to systemic steroids). There were no associa-
tions with syndactyly in the Norwegian data. and no sig-
nificant association in the Welsh data. There were no
associations with club foot and aortic valve atresia/steno-
sis in the Welsh data (data not shown). For severe
CHD, common AV canal and aortic valve atresia/stenosis
(both included in severe CHD subgroup), the increased
odds seems to be associated with exposure to the combi-
nation of inhaled steroids and long-acting beta-2-agonists.
For limb reduction defects the odds are significantly
increased after exposure to beta-2-agonists, but with no
increased odds for inhaled steroids. The associations with
renal dysplasia seem driven by exposure to short-acting
beta-2-agonists (2.37; 99% CI 1.20–4.67). There were no
significant associations after exposure to long-acting beta-
2-agonists, but the total number of exposed fetuses was
small.
The association of anal atresia/stenosis with exposure to
inhaled steroids was significant at the 1% level (OR 3.4;
99% CI 1.15–10.04). There was no further significant asso-
ciations found in the literature at 5% level for anomaly-
exposure signals.5
Despite significant associations between use of inhaled
beta-2-agonists and cleft palate and gastroschisis in a previ-
ous analysis in an overlapping study population with differ-
ent exposure data source,5 we found no significant
associations here: the odds ratio was 1.05 (99% CI 0.44–
2.51, n = 9) for cleft palate and 1.08 (99% CI 0.37–3.15,
n = 6) for gastroschisis.
Sensitivity analysis with a more strict exposure defini-
tion reduced total exposure by approximately 50–80%.
For cataract and aortic valve atresia/stenosis, there were
too few exposed cases to analyse. For club foot ORs
were still increased (1.57), but the statistical significance
disappeared. For the associations common AV canal and
combination treatment, anal atresia and inhaled steroids
and renal dysplasia and SABA, results were still signifi-
cant and ORs were higher. For the association severe
CHD and combination treatment, the OR was increased,
but not significantly (OR 2.63, 99% CI 0.98–7.05)
(Table S2).
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Figure 1. Associations between use of the seven asthma medication groups and each anomaly subgroup with at least three exposed cases: Results
from Norway, Wales and Funen, Denmark combined.
6 ª 2016 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
Royal College of Obstetricians and Gynaecologists.
Garne et al.
Discussion
Main findings
Our cohort study found that exposure to different types of
asthma medications was associated with similar increased
risks of a major congenital anomaly (OR close to 1.2 for all
medication types), but only few significant associations for
specific groups of congenital anomalies. This may be
explained by the maternal asthma being causal, rather than
the fetal exposure to asthma medications being causal. We
found very small differences between OR and adjusted OR
for all major congenital anomalies, showing that there is
little if any confounding by maternal age or socioeconomic
position.
Strengths and limitations
The strength of this study is the population-based design
with congenital anomaly registries linked to prescription
databases. Furthermore, the medication data were collected
prospectively by the databases and therefore maternal recall
bias is not a problem. It is a limitation that we do not
know whether the pregnant women took the prescribed
medications. Inhaled beta-2-agonists may not be taken reg-
ularly and could be prescribed for occasional use. For this
reason, the inhaler may also have been prescribed outside
the defined exposure period, so that women who actually
did use their inhalers during the first trimester were mis-
classified. Even with a cohort of 519 242, the number of
exposed cases for specific anomalies was often very small,
leading to large uncertainty of the estimates, particularly as
data could not be pooled and a meta-analysis approach
had to be applied. Bias is unlikely to occur due to the dif-
ferent GA at inclusion in Wales (24 instead of 20 weeks),
as the likelihood of being born and diagnosed with a mal-
formation is not higher at GA 20–23 weeks than at
24 weeks and the proportion of missed cases and controls
is very small (0.15%). As several asthma medications are
often used together, it is hard to disentangle the possible
effects of the individual asthma drugs. Adjustment for
socioeconomic status was crude due to the limited avail-
ability of information and the small number of cases in
some anomaly subgroups, and may not have been sufficient
to account for the complex effect of socioeconomic posi-
tion on risk of congenital anomaly. The study is not able
to distinguish between the potential teratogenic effect of
the maternal asthma and the potential teratogenic effects of
asthma medications. As asthma has been linked to environ-
mental toxins, the link to the congenital anomalies could
be the toxins and not the disease or the medication. The
large number of comparisons made means that significant
associations must be interpreted with caution, particularly
where not confirmed by other studies.
Interpretation
Two other cohort studies have found almost the same
increased odds of congenital anomaly in general as in our
Table 3. Meta-analysis odds ratios for associations between congenital anomaly subgroups and prescription of asthma medications, showing
associations significant at the 1% level. Adjusted odds ratios given for anomalies with at least 15 exposed cases
Anomaly Medication Exposed cases Meta-analysis OR* (99% CI) I2
Congenital cataract Any asthma medications 9 2.61 (1.03–6.61) NA
Inhaled corticosteroids 5 3.53 (1.05–11.81) 0
Severe CHD Combination treatments 21 1.97 (1.12–3.49) 36
Aortic valve atresia/stenosis Combination treatments 5 4.21 (1.29–13.7) 67
AVSD Any asthma medications 10 3.15 (1.32–7.51) 0
Combination treatments 6 6.05 (2.04–17.97) 30
Anal atresia/stenosis** Inhaled corticosteroids 6 3.40 (1.15–10.04) 0
Renal dysplasia Any asthma medications 18 2.16 (1.14–4.09) 0
Inhaled beta-2-agonists 16 2.30 (1.17–4.52) 0
Short-acting beta-2-agonists 16 2.37 (1.20–4.67) 0
Limb reduction Any asthma medications 20 1.97 (1.08–3.6) 56
Inhaled beta-2-agonists 18 2.22 (1.18–4.20) 74
Short-acting beta-2-agonists 18 2.32 (1.23–4.38) 76
Systemic corticosteroids 3 4.93 (1.10–22.14) 0
Club foot Any asthma medications 44 1.52 (1.01–2.27) 0
Systemic corticosteroids 6 3.49 (1.21–10.06) 71
Syndactyly Any asthma medications 20 1.85 (1.02–3.38) 59
Short-acting beta-2-agonists 16 2.00 (1.02–3.90) 78
*Adjusted for maternal age and socio-economic position.
**Found in previous literature (Lin et al.20).
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study. A study in Canada, including 13 280 pregnancies
with at least one diagnosis of asthma and one prescription
for asthma medications, found an adjOR of 1.34 (95% CI
1.22–1.47) for any major congenital anomaly.19 A study
from the Swedish Medical Birth registry included women
who reported use of anti-asthmatic medication in the first
trimester of pregnancy.4 Here adjOR for any major congen-
ital anomaly was 1.09 (95% CI 1.03–1.12). Both studies
included live- and stillbirths, but not TOPFA, as in our
study.
Our study showed an association of anal atresia and
inhaled corticosteroids (OR 3.4, 99% CI 1.15–10.04). A
case–control study found an increased odds of isolated
anal atresia with an OR of 2.12 (95% CI 1.09–4.12) for
exposure to anti-inflammatory asthma medications
including inhaled and systemic corticosteroids and
adjusted for other asthma medications.20 A cohort study
from Sweden in 1995–2004 found an OR of 1.69 (95%
CI 1.11–2.56) after exposure to any asthma medication,21
but in the next publication from the same population
for the years 1996–2011 the OR for anal atresia was
reduced (OR 1.21, 95% CI 0.78–1.87).4 There is limited
information in the literature about the risk of specific
congenital anomalies after exposure to inhaled corticos-
teroids. An increased risk for hypospadias has been
described (OR 1.8, 95% CI 1.1–3.0) after exposure to
inhaled and nasal corticosteroids.22 The EUROmediCAT
case-malformed control study did not find increased
odds for any specific congenital anomaly after exposure
to inhaled corticosteroids,5 although the odds ratios of
exposure to inhaled corticosteroids for anal atresia and
adjusted for exposure to other asthma medications was
non-significantly increased (OR 1.49, 95% CI 0.74–3.02).
There are few studies on the risk of congenital anomalies
after exposure to LABA and these have a limited number
of exposed cases. A Canadian study found an increased
odds of CHD based on seven exposed cases (OR 2.38, 95%
CI 1.11–5.10).23 Our study found an increased odds of sev-
ere CHD after exposure to the combined treatment with
LABA and inhaled steroids, and also a significantly
increased odds for aortic valve atresia/stenosis and com-
mon AV canal separately. These associations may be caused
by the medication exposure, but they may also be
explained by the asthma severity with the need for daily
use of long-acting beta-2-agonists. The EUROmediCAT
case-malformed control study found an association between
renal dysplasia and the combined treatment.5 We are not
aware of other published studies evaluating the risk of the
combined treatment with LABA and inhaled steroids and
congenital anomalies.
The associations between SABA and renal dysplasia, limb
reduction defects and syndactyly have not been described
previously. The ORs were from 2.00 to 2.37, but decreased
and statistical significance disappeared when we restricted
exposure to at least two prescriptions, where we could be
more confident that exposure had indeed occurred to these
intermittently taken medications. However, these findings
need future attention and possible confirmation in other
populations.
Significant results from other studies include exposure to
beta-2-agonists and increased odds of cleft palate, cleft lip
and palate, esophageal atresia, omphalocele and gastroschi-
sis.20,24,25 None of these beta-2-agonist exposure–congenital
anomaly combinations was significant in our study at the
5% level (no confirmation of previous literature signals).
The EUROmediCAT case-malformed control study con-
firmed two of these signals (cleft palate and gastroschisis)
using a different data source for exposure (medical records)
and a different methodology comparing the signal anomaly
cases with malformed controls.26
The association of congenital cataract and exposure to
inhaled steroids was based on five cases from Wales with
no exposed cases in Norway and Funen, Denmark. The
finding is of interest as cataract has been described as a rare
adverse effect of inhaled steroids in children and adults.27
The prevalence of cataract in the EUROCAT registry in
Wales is higher than in the two other registries, probably
explained by better ascertainment of congenital eye anoma-
lies in general.
Exposure to systemic steroids may be a marker of disease
severity. For the all-anomaly group, the association with
systemic steroids was associated with higher OR than for
exposure to inhaled medications (OR 1.51, 99% CI 1.03–
2.22). This may also reflect greater bioavailability. However,
the low number of pregnancies exposed to systemic steroid
limited our possibilities for finding associations with speci-
fic congenital anomalies. Furthermore, systemic steroids
may have been taken during hospital admissions and these
exposures are not covered by the prescription databases.
The higher exposure rate to asthma medications in
Wales may be explained in several ways. The Wales data-
base captured prescriptions issued to the woman, whereas
the databases in Norway and Denmark captured prescrip-
tions dispensed at the pharmacy. To the extent that this
explains the higher exposure rate, it will also cause hetero-
geneity in the estimates, as exposure misclassification is
higher in Wales. We note, however, that for the significant
associations with high heterogeneity, the heterogeneity did
not generally take the form of a lower OR in Wales.
Another explanation for a higher prevalence of asthma in
Wales is the socio-demographic differences described in
Table S1 (maternal age, smoking, body mass index, socio-
economic position). The differences in asthma prevalence
and prescribing of asthma medication during pregnancy
between Wales and Scandinavia has been described in other
studies.28
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Conclusions
Most of the specific congenital anomalies have prevalence
rates between 1 in 1000 and 1 in 10 000 births. Even with
an OR after exposure to beta-2-agonists of between 2 or 3,
the risk for the individual pregnant woman is low. Mater-
nal asthma exacerbation during the first trimester of preg-
nancy has been reported to be associated with an increased
risk of congenital anomalies29 and exacerbation during
pregnancy may be associated with other unfavourable preg-
nancy outcomes such as preterm birth and pre-eclampsia.30
The general consensus is that uncontrolled asthma increases
perinatal risks, whereas well-controlled asthma reduces
these risks.3,31 Therefore, pregnant women should continue
to use the prescribed inhaled corticosteroids, where we find
little evidence of teratogenic risk, for optimal asthma con-
trol and to reduce the need for beta-2-agonists and sys-
temic corticosteroids, which may be associated with greater
teratogenic risk.
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